May 17, 2024

Moleculin Biotech Addresses Significant Unmet Need with Glioblastoma Trial

Pharmaceutical company, Moleculin Biotech (Nasdaq: MBRX), has initiated an Investigator-initiated Phase 2 study evaluating WP1066 in combination with radiation therapy for the treatment of glioblastoma. The study is an open-label, multi-arm trial which will measure progression-free survival and the tumor microenvironment following treatment. Moleculin’s share price climbed 6.0% in trading on Wednesday and Thursday after… [Read More]
May 17, 2024

PRISM New Energy Index Company Spruce Power (SPRU) Announces Q1 Earnings

Owner and operator of residential solar power, Spruce Power Holding Corp. (SPRU) announced earnings yesterday that improved on EPS ($0.13) vs FactSet ($1.06). First quarter revenues came in at $18.3M compared to $18.1M a year ago and were attributed to incremental revenues from the Tredegar acquisition completed in August 2023. The company reported a net… [Read More]
May 16, 2024

Oncocyte Unveils Q1 2024 Achievements: Strategic Partnerships and Diagnostic Innovations Anticipated to Propel Growth Over Next 12 to 18 Months

Company Expanding Transplant Initiatives to Pave the Way for Global Market Penetration and Enhanced Patient Care Oncocyte (NASDAQ:OCX), a leading precision diagnostics company, reported its financial results for the first quarter ended March 31, 2024, revealing significant strides in its commercialization efforts and strategic developments. The company announced a global commercialization partnership with Bio-Rad Laboratories… [Read More]
May 16, 2024

Soligenix Highlights Positive Clinical Results Published in Peer-Reviewed Dermatology Journal

Shares in late-stage biopharmaceutical company, Soligenix, Inc. (Nasdaq: SNGX), climbed more than 7.0% on Thursday morning after the company announced that the results of its compatibility study evaluating HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL) were published in the peer-reviewed Journal of the European Academy of Dermatology & Venereology (JEADV) Clinical… [Read More]
May 16, 2024

Biogen and Ionis to Terminate Development of ALS Candidate

In a setback to the ALS community, Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) have announced a decision to terminate development of BIIB105 (ION541). BIIB105, the companies’ candidate for the treatment of amyotrophic lateral sclerosis (ALS) was being evaluated in a Phase 1/2 study and failed to meet primary and secondary endpoints… [Read More]
May 16, 2024

Ideal Power IPWR Announces Q1 Earnings Energizing Investors on Sales Momentum

Ideal Power Inc. (IPWR) announced its Q1 financials and expects that the solid-state circuit breaker market, served by their SymCool power module will grow revenue. Furthermore, their Phase II product development program with top global automaker, Stellantis (STLA) was completed ahead of schedule. The company also announced the addition of its first distributor Richardson Electronics… [Read More]
May 16, 2024

NeuroOne Reports 195% Increase in Product Revenue

NeuroOne Medical Technologies (Nasdaq: NMTC) has announced its operating results for the second quarter fiscal year 2024 ended March 31, 2024, reporting a 195% increase in product revenue. During the quarter, the company also raised an additional $2.0 million using the ATM Program. NeuroOne CEO, Dave Rosa, said the company had made “excellent progress across… [Read More]
May 16, 2024

Voyager Therapeutics Doses First Participants in Alzheimer’s Disease Trial

Voyager Therapeutics (Nasdaq: VYGR) has dosed the first participants in its Phase 1a trial of VY-TAU01, an investigational anti-tau antibody developed to inhibit the spread of pathological tau in Alzheimer’s disease. The 48-patient, single site study will evaluate the safety and pharmacokinetics of VY-TAU01 in healthy adult volunteers. Voyager believes that VY-TAU01 has the potential… [Read More]
May 16, 2024

Vanda Pharmaceuticals Reports Positive Results in Motion Sickness Trial

The FDA has not approved a new medication for motion sickness in over 40 years, and Vanda Pharmaceuticals (Nasdaq: VNDA) may be on track to change that. The company’s share price rose by 5.0% on Wednesday after it reported positive results from a second Phase 3 clinical trial evaluating tradipitant in motion sickness. Vanda said… [Read More]